FDA Single-Trial Drug Approval Pathway

What Does the FDA's Single-Study Approval Standard Mean?

The traditional U.S. drug approval framework, codified after the 1962 Kefauver-Harris Amendments, generally expects two adequate and well-controlled clinical trials demonstrating substantial evidence of effectiveness. Under the FDA Modernization Act of 1997, Section 115 already permits the agency to rely on a single adequate study plus confirmatory evidence in certain situations. The current policy direction formalizes and broadens that flexibility, particularly for drugs targeting serious or life-threatening conditions.

In practice, a single-trial pathway depends on the strength of the pivotal study: large sample size, statistically robust endpoints, internal consistency across subgroups, and corroborating mechanistic, biomarker, or real-world data. The FDA has long applied this approach selectively in oncology, rare diseases, and pediatrics, where conducting two independent trials may be infeasible. Codifying it more broadly aims to reduce duplication when one trial already provides compelling evidence.

How Could This Change Affect Patients and Prescribers?

For patients with serious illnesses such as advanced cancers, ALS, or rare genetic disorders, faster approval can translate to meaningful access years earlier. Industry analyses suggest that removing the second pivotal trial requirement can shorten clinical development by 18 to 36 months and substantially reduce costs, potentially encouraging investment in conditions with small patient populations.

However, regulatory researchers have noted that drugs approved on a single trial historically show higher rates of post-approval label changes, including new safety warnings. Clinicians will need to weigh narrower pre-approval evidence against patient need, and the FDA's post-marketing requirements, including Phase 4 commitments and adverse event reporting through FAERS, become even more critical. Robust real-world evidence platforms, such as Sentinel, are expected to play a larger confirmatory role.

What Are the Risks of Approving Drugs on Less Evidence?

Independent replication has long been a cornerstone of medical evidence. A single positive trial, even when well-powered, carries a higher residual risk of false-positive findings due to chance, unrecognized bias, or population-specific effects. Peer-reviewed analyses published in JAMA and BMJ have documented cases where second confirmatory trials failed to reproduce initial benefits, leading to withdrawals or restricted indications.

To mitigate these risks, the FDA typically pairs single-trial approvals with conditions such as confirmatory post-marketing trials, restricted distribution programs, or REMS (Risk Evaluation and Mitigation Strategies). Transparency about the evidentiary basis of approval, including clear labeling and prescriber education, remains essential so that informed benefit-risk decisions can be made at the point of care.